# Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle

Authorised

- Bovine parainfluenza virus 3, strain INT2-2013, Live
- Bovine respiratory syncytial virus, strain Jencine-2013, Live

## Product identification

**Medicine name:**
Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle

**Active substance:**
Bovine parainfluenza virus 3, strain INT2-2013, Live

Bovine respiratory syncytial virus, strain Jencine-2013, Live

**Target species:**
Cattle

**Route of administration:**
Nasal use

## Product details

**Active substance and strength:**

Bovine parainfluenza virus 3, strain INT2-2013, Live
4.80 log10 50% tissue culture infectious dose / 2.00 millilitre(s)

Bovine respiratory syncytial virus, strain Jencine-2013, Live
5.00 log10 50% tissue culture infectious dose / 2.00 millilitre(s)

**Pharmaceutical form:**
Nasal spray, suspension

**Withdrawal period by route of administration:**

**Nasal use:**

- **Cattle**
  - Meat and offal. no withdrawal period zero days

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**
QI02AD07

**Legal status of supply:**
Veterinary medicinal product subject to veterinary prescription

**Authorisation status:**
Valid

**Authorised in:**
Norway

**Available in:**
Norway

**Package description:**
Cardboard box 5 x 5 doses of lyophilisate and 5 x 10 ml of solvent
Cardboard box with 20 doses of lyophilisate and cardboard box with 40 ml of solvent
Cardboard box with 1 dose of lyophilisate and 2 ml of solvent.
Cardboard box 5 x 1 dose of lyophilisate and 5 x 2 ml of solvent
Cardboard box 5 doses of lyophilisate and 10 ml of solvent.
Cardboard box 10 doses of lyophilisate and 20 ml of solvent.
Cardboard box with 10 doses of lyophilisate and cardboard box with 20 ml solvent
Cardboard box with 20 doses of lyophilisate and 40 ml of solvent

## Additional information

**Entitlement type:**
Marketing Authorisation

**Legal basis of product authorisation:**
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

**Marketing authorisation holder:**
Intervet International B.V.

**Marketing authorisation date:**
26/06/2019

**Manufacturing sites for batch release:**
Intervet International B.V.

**Responsible authority:**
Norwegian Medical Products Agency

**Authorisation number:**
18-12322

**Date of authorisation status change:**
26/06/2019

**Reference member state:**
Netherlands

**Procedure number:**
NL/V/0257/001

**Concerned member states:**
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents